1-[Alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-pyridin-4-yl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)-one derivatives
申请人:SANOFI-SYNTHELABO
公开号:EP1184385A1
公开(公告)日:2002-03-06
The invention relates to a dihydroimidazo[1,2-a]pyrimidone derivative represented by formula (I) or a salt thereof:
wherein :
X represents hydrogen atoms, a sulphur atom or an oxygen atom;
Y represents a bond, an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group, a carbonyl group, a nitrogen atom being optionally substituted or a methylene group optionally substituted;
R1 represents a 2, 3 or 4-pyridyl group optionally substituted;
when Y represents a bond, a methylene group optionally substituted or a carbonyl group, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a C1-4 alkylthio group, a C1-4 alkoxy group, a naphthyl group, a phenylthio group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring ; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents;
when Y represents an oxygen atom, a sulphur atom, a sulfonyl group, a sulfoxyde group or a nitrogen atom being optionally substituted, then R2 represents a C1-6 alkyl group, a C3-6 cycloalkyl group, a C1-2 perhalogenated alkyl group, a C1-3 halogenated alkyl group, a naphthyl group, a benzyl group, a phenyl ring, a pyridyl ring, an indole ring, a pyrrole ring, a thiophene ring, a furan ring or an imidazole ring; the benzyl group, the phenyls, the naphthyl or the rings being optionally substituted by 1 to 3 substituents;
and n represents 0 to 3.
The invention relates also to a medicament comprising the said derivative or a salt thereof as an active ingredient which is used for preventive and/or therapeutic treatment of a neurodegenerative disease caused by abnormal activity of GSK3β.
该发明涉及一种由
化学式(I)表示的二氢
咪唑并[1,2-a]
嘧啶酮衍
生物或其盐:其中:X代表氢原子、
硫原子或氧原子;Y代表键、氧原子、
硫原子、磺酰基、磺氧基、羰基、氮原子(可选择性取代)或取代的亚甲基基团;R1代表可选择性取代的2、3或4-
吡啶基团;当Y代表键、可选择性取代的亚甲基基团或羰基时,R2代表C1-6烷基基团、C3-6环烷基基团、C1-2
全氟烷基基团、C1-3卤代烷基基团、C1-4烷
硫基团、C1-4烷氧基团、
萘基团、苯
硫基团、苄基团、苯环、
吡啶环、
吲哚环、
吡咯环、
噻吩环、
呋喃环或
咪唑环;苄基团、苯基、
萘或环可选择性地被1至3个取代基取代;当Y代表氧原子、
硫原子、磺酰基、磺氧基或氮原子(可选择性取代)时,R2代表C1-6烷基基团、C3-6环烷基基团、C1-2
全氟烷基基团、C1-3卤代烷基基团、
萘基团、苄基团、苯环、
吡啶环、
吲哚环、
吡咯环、
噻吩环、
呋喃环或
咪唑环;苄基团、苯基、
萘或环可选择性地被1至3个取代基取代;n代表0至3。该发明还涉及一种药物,其包括所述衍
生物或其盐作为活性成分,用于预防和/或治疗由GSK3β异常活性引起的神经退行性疾病。